Device RAC Exam Questions with Approved Answers- 100% Pass

Which division has primary jurisdiction over a vascular graft with an antibiotic based on primary mode of action? A. CDER B. CBER C. CDRH D. OCP - Answer-C. CDRH In this combination of a device and a drug, the primary mode of action is that of the vascular graft (device). The antibiotic is supportive in this case. A company wants to modify its legally marketed device such that the modification does not affect the intended use or alter the fundamental scientific technology of the device. If the design outputs of the modified device meet the design input requirements, this change would be best filed as a(n): A. Special 510(k) B. Abbreviated 510(k) C. Traditional 510(k) D. De novo 510(k) - Answer-A. Special 510(k) A Special 510(k) is allowed if a modification to the legally marketed device is being made that relies on compliance with design controls, including design validation. The incentive provided for manufacturers to choose this option is that ODE intends to process special 510(k)s within 30 days of receipt. See the CDRH guidance published in 1998 entitled The New 510(k) Paradigm - Alternate Approaches to Demonstrating Substantial Equivalence in Premarket Notifications. Under the statutory violations, failure to meet 510(k) requirements for a device that is required to have a 510(k) and is in commercial distribution is considered to be: A. Adulteration. B. Improper use C. Misbranded D. Fraudulent - Answer-C. Misbranded A marketed device that needs a 510(k) for commercialization but failed to comply with the requirements is considered to be Misbranded. See the FD&C Act, 502(o). A company's competitor is marketing a Class II suture which dissolves during the third week of use. The company's current product has to be removed by a physician. However, a change in weaving configuration gives this product the same dissolving time as the competitor's. When can the company's new suture be marketed? A. This requires a new 510(k) since significant change in product instructions might affect efficacy. B. After submission in a periodic report C. After reporting clinical studies in an annual report D. After submission of labeling change - Answer-A. This requires a new 510(k) since significant change in product instructions might affect efficacy. A new intended use requires a 510(k) clearance. A physician reports to a manufacturer that a patient was hospitalized with acute sepsis after treatment with an approved device. This side effect is not listed in the package insert. This event must be reported by the manufacturer to FDA no later than: A. 5 calendar days B. 15 calendar days C. 30 calendar days D. The next quarterly or annual report - Answer-C. 30 calendar days Serious injury must be reported within 30 days even if it is expected and stated in the IFU A handling and storage system for medical devices must always include: A. Procedures for rotation of stock B. Separate rooms or cages for release and quarantine products C. Procedures for product receipt and transfer D. Environmentally controlled areas for products with shelf life - Answer-C. Procedures for product receipt and transfer Procedures for receipt and transfer of products are required; see 21 CFR 820.150(b). You have modified your 510(k) cleared device with a special 510(k). In which of the following cases would you need to create a new listing for the device? A. You have added new sizes and shapes in the product portfolio. B. You have changed the material composition of the device. C. You have changed the package of the device. D. None of the above. - Answer-D. None of the above. According to 21 CFR 807.22(b), a separate form FDA-2892 shall be submitted for each device or device class listed with the FDA. Devices having variations in physical characteristics such as size, package, shape, color or compo